Teva Oncology

Patient Support Services Guide 2018


Teva CORE
888-587-3263
Teva Cares
877-237-4881

Teva Oncology offers access to oncology medications from Teva through Teva Comprehensive Oncology Reimbursement Expertise (CORE) and the Teva Cares Foundation Patient Assistance Program.

The complete list of oncology drugs from Teva Oncology, their indications, and available programs is provided in the Table.

Teva CORE

Teva CORE is designed to provide a reimbursement support program and online tools and resources for oncology medications from Teva Oncology.

Teva CORE can provide assistance with benefit verification, coverage determination, prior authorizations, and letters of medical necessity, as well as personalized support throughout the claims and appeals processes.

For uninsured patients, Teva CORE can identify additional resources to assist patients with the costs of their treatment.

The SYNCare support program is available for patients taking Synribo (omacetaxine mepesuccinate). Services that the program offers include:

  • Arranging for the direct delivery of Synribo to patients
  • Supplying materials for injection, cleanup, and disposal of injection waste
  • A toll-free hotline with trained personnel.

Patients can call 844-796-2273 or can visit this website for more information.

The Granix Patient Savings Program is available for commercially insured, cash-paying patients taking Granix (tbo-filgrastim) and covers the pharmacy benefit for this drug. Eligible patients will pay no more than $0, and receive savings up to $14,000 annually.

No patient enrollment is required for this program, and the offer applies specifically to the syringe without needle guard. For more information about the Granix Patient Savings Program, visit this website or call 888-587-3263.

Teva Cares Foundation

Teva Cares Foundation Patient Assistance Program provides oncology medications at no cost to eligible patients who meet certain income and insurance criteria.

Eligibility

Teva CORE

Patients may qualify for assistance through Teva CORE if they:

  • Have been prescribed an oncology medication from Teva Oncology, including Bendeka (bendamustine hydrochloride), Granix, Synribo, Treanda (bendamustine hydrochloride), or Trisenox (arsenic trioxide)
  • Meet the annual household income requirements.

For more information about eligibility requirements, call 888-587-3263.

Teva Cares Foundation Patient Assistance Program

Patients may qualify for the Teva Cares Foundation Patient Assistance Program if they:

  • Are a US resident
  • Have been prescribed an oncology medication from Teva Oncology
  • Do not have prescription drug coverage
  • Meet annual household income requirements.

More information about eligibility requirements can be obtained online or by calling 877-237-4881.

Application & Enrollment

Teva CORE

Patients and prescribers must coordinate to complete their designated sections of the application.

Prescribers enrolling in the Teva CORE program can fill out a standard application form or can submit the form online through assistPoint. assistPoint provides oncology practices with the ability to register patients electronically to more efficiently access Teva CORE services.

For more information about assistPoint visit this website.

Teva Cares Foundation Patient Assistance Program

Drug-specific application forms for the Teva Cares Foundation Patient Assistance Program, and the Teva CORE program.

The forms must be completed and faxed to the number on the enrollment form, or mailed directly to the program’s address listed on the form.

Proof of income is required from all sources and for all household members, as well as a prescription for an improved indication (if required).

Table Teva Oncology/Supportive Care Drugs

Drugs
Indications
Patient support programs

Drug
Bendeka (bendamustine hydrochloride)
Indication
Chronic lymphocytic leukemia; indolent B-cell non-Hodgkin lymphoma

Drug
Fentora (fentanyl buccal tablet), CII
Indication
Breakthrough pain in cancer

Drug
Granix (tbo-filgrastim)
Indication
Severe neutropenia

Drug
Synribo (omacetaxine mepesuccinate)
Indication
Chronic myeloid leukemia

Drug
Treanda (bendamustine hydrochloride)
Indication
Chronic lymphocytic leukemia; indolent B-cell non-Hodgkin lymphoma

Drug
Trisenox (arsenic trioxide)
Indication
Acute promyelocytic leukemia